Healthcare / Medical Instruments & SuppliesTaipei Exchange
$72.30
-0.20 (-0.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-112.3M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
66.9x
↑EV/EBITDA
15.9x
↑ROE
2.8%
↑Gross Margin
59.1%
↑Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+30.2%
FCF CAGR
—
FCF margin
-9.9%
FCF / Net income
-2.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.13B · net income $51.2M · FCF $-112.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.13B | $1.13B | $859.8M | $605.5M | $511.9M |
| Net Income | $51.2M | $51.2M | $103.1M | $97.7M | $128.9M |
| EBITDA | $241.7M | $241.7M | $271.8M | $164.2M | $172.0M |
| EPS | — | — | 2.18 | 2.31 | 3.13 |
| Gross Margin | 59.1% | 59.1% | 69.8% | 79.7% | 81.6% |
| Operating Margin | 11.4% | 11.4% | 15.0% | 19.6% | 24.8% |
| Net Margin | 4.5% | 4.5% | 12.0% | 16.1% | 25.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.54 | 0.08 | 0.01 |
| Current Ratio | 2.07 | 2.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-112.3M | $-112.3M | $-205.2M | $-102.3M | $94.9M |
| Returns | |||||
| ROE | 2.8% | 2.8% | 6.2% | 6.2% | 14.7% |
| Valuation | |||||
| P/E | 66.94 | 66.94 | 50.67 | 42.95 | 21.36 |
| EV/EBITDA | 15.93 | 15.93 | 20.87 | 24.00 | 14.60 |
| P/B | 1.87 | 1.87 | 3.14 | 2.66 | 3.17 |
| Growth & Yield | |||||
| Revenue Growth | 31.5% | 31.5% | 42.0% | 18.3% | — |
| EPS Growth | — | — | -5.6% | -26.3% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.3%
Start / end P/E
n/dx → n/dx
EPS bridge
2.18 → n/d
Residual
-31.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.